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BCP; Blood crystalloid cardioplegia   
	 
CCP; Crystalloid cardioplegia        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	 
Cl; Confidence interval      
LA/Ao; Left atrium to aortic root ratio    
LVIDDN; Standardized left ventricular end-diastolic diameter     
 
MR; Mitral regurgitation      
MVD; Mitral valve degeneration     
OR; Odds ratio       
SERT; Serotonin Transporter     
UDP; Unilateral diaphragmatic paralysis    
XPC; Xeroderma Pigmentosum Complementation Group C 
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Introduction: In dogs, mitral valve degeneration (MVD) is the most common cause of 
acquired heart disease. MVD is common in small dogs, and its incidence is high in certain 
dog breeds. However, the genetic mechanisms underlying the development of MVD have not 
been elucidated, and no curative treatment has been performed. Treatment of MVD is usually 
medical, but in severe cases, secondary to congestive heart failure, surgery may be performed. 
The prognosis of MVD is limited in patients with congestive heart failure. In recent years, 
surgical treatment for MVD has been performed in dogs, and the prognosis has improved. 
However, to date, information on the risk factors and complications of surgical treatment of 
MVD is limited, and the impact on surgical outcomes is unknown. 
The purpose of this study was to investigate the risk factors for complications and the effects 
of complications on surgical outcomes in order to improve the clinical outcomes of surgical 
treatment of MVD in dogs. Regarding the genetic aspect, we focused on Chihuahuas because 
they have a large population in Japan and account for a large proportion of dogs undergoing 
surgical treatment. Furthermore, we investigated possible genes responsible for MVD in 
Chihuahuas. 
 
Chapter 1 Risk factors for ventricular fibrillation following aortic cross-clamping release 
during mitral valve repair in dogs 
Background: Although hearts with ventricular fibrillation have electrical ventricular 
excitement, the pumping function is lost. If treatment is not immediately successful, fatal 
arrhythmia may develop. In this study, we investigated the risk factors for ventricular 
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fibrillation after releasing aortic cross-clamping, a fatal complication during surgery, with the 
aim of improving surgical outcomes. 
Methods: A total of 237 dogs that underwent mitral valve repair from November 2015 to 
September 2017 were recruited. Crystalloid cardioplegia (CCP) or blood-CCP (BCP) 
obtained by mixing CCP with autologous blood at a ratio of 1:1 was used. The age, body 
weight, left atrial-to-aortic diameter ratio (LA/Ao), standardized left ventricular end-diastolic 
diameter (LVIDDN), aortic cross-clamping time, cardioplegia type, and cardioplegia dose as 
predictors of ventricular fibrillation were recorded. In addition, the effects of different 
myocardial protective solutions were evaluated by comparing the amount of transfusion used 
during surgery, survival rate 1 month after surgery, and effect of reducing the heart size. 
Results: In the group of patients with ventricular fibrillation, body weight, LA/Ao, LVIDDN, 
and aortic block time significantly increased, and LVIDDN was closely related to the 
occurrence of ventricular fibrillation. When BCP was used as the cardioplegic solution, the 
incidence of ventricular fibrillation significantly reduced compared to when CCP was used. 
The incidence of intraoperative blood transfusion was significantly lower in the BCP group. 
One month postoperatively, the survival rate or reduction in the heart size did not differ 
between cardioplegia types. 
Conclusion: High body weight, LA/Ao, LVIDDN, and aortic block time are risk factors for 
ventricular fibrillation after releasing aortic cross-clamping. For cardioplegia, BCP was 
confirmed to be as safe as CCP. Furthermore, the use of BCP reduced the incidence of 




Chapter 2 Unilateral diaphragmatic paralysis following mitral valve repair in dogs  
Background: The phrenic nerve innervates the diaphragm, the main respiratory muscle. 
Damage to the phrenic nerve causes unilateral diaphragmatic paralysis (UDP), resulting in 
diaphragmatic dysfunction. In this study, we evaluated the incidence and recovery time of 
UDP, which is a postoperative complication, as well as the effect on survival outcomes 
following intraoperative complications. 
Methods: The subjects were 284 dogs who underwent mitral valve repair from August 2014 
to March 2017. In an inspiratory dorsoventral image obtained with chest X-ray the day after 
operation, if the left diaphragm was raised more than one intercostal level from the right 
diaphragm, the patient was diagnosed with UDP. The recovery time was evaluated at the time 
of discharge from the hospital 1 month postoperatively and at the 3-month follow-up. 
Results: In this study, the incidence of UDP was 30.3%. Almost all cases of UDP had 
improved 3 months postoperatively. The presence/absence of UDP was not significantly 
associated with postoperative death. However, the incidence of UDP was significantly higher 
among patients who died of respiratory failure than among patients who died of other causes. 
Furthermore, many patients who died of respiratory failure had respiratory disease before 
surgery. 
Conclusion: Although the incidence of UDP is high after mitral valve repair, there is early 
improvement. The involvement of UDP in the surgical results is unlikely to be a direct cause 
of death, but combined with other respiratory diseases, patients are at high risk of death due 




Chapter 3 Search for candidate genes for mitral regurgitation in Chihuahua 
Background: Mitral regurgitation (MR) is common in the dog breed Chihuahua. Furthermore, 
in the studies reported in chapters 1 and 2, most patients who underwent surgical treatment 
for MVD were Chihuahuas. Therefore, the aim of this study was to perform a survey of 
candidate genes for MR in Chihuahuas. 
Methods: In this study, we recruited Chihuahuas aged 7 years or older. Participants without 
MR or with minimal MR were considered healthy. The MR group comprised patients with 
severe MR and cardiac expansion after developing American College of Veterinary Internal 
Medicine stage B2. DNA was extracted from peripheral blood of each individual, and 
nucleotide sequences of the healthy and MR groups were compared to search for a candidate 
gene for the cause. Polymorphisms were investigated in the serotonin transporter (SERT) 
gene, which is associated with MR in Maltese dogs, and the xeroderma pigmentosum 
complementation group C (XPC) and DCHS1 genes, which are associated with mitral valve 
prolapse in humans, were compared. 
Results: Regarding SERT, the nucleotide sequences of the healthy and MR groups were the 
same in all exon 13 regions examined, and no apparent gene polymorphism was observed. 
In XPC, an adenine-guanine polymorphism was observed at the 902nd amino acid, but the 
polymorphism ratio was not significantly different between the healthy and MR groups. The 
amino acids translated by the adenine-guanine polymorphism were the same. In DCHS1, two 
gene polymorphisms were found in exon 19 equivalents, and one gene polymorphism was 
found in exon 21 equivalents. One of the observed polymorphisms was a missense mutation 
that caused an amino acid change, but there were no differences in the percentage of 
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polymorphisms between the healthy and MR groups. 
Conclusion: Genetic polymorphisms of XPC and DCHS1 were observed in Chihuahuas, but 
their associations with MR were considered to be low. In addition, in this study, no difference 
in the nucleotide sequence of SERT was observed between the healthy and MR groups in 
Chihuahuas, suggesting that the candidate gene may differ across dog breeds. 
 
Summary: We demonstrated the risk factors for typical complications of MVD surgery and 
effects of complications on surgical outcomes and identified candidate genes associated with 
MR in Chihuahuas. High levels of LVIDDN were an excellent risk factor for ventricular 
fibrillation following aortic cross-clamping release, a fatal arrhythmia. BCP, which mixes 
autologous blood with myocardial protective fluid, was found to be an effective method to 
reduce the incidence of ventricular fibrillation. The use of BCP was a new technique 
suggested to improve surgical outcomes. 
Although respiratory failure is known to be a major cause of postoperative death, this study 
revealed that UDP combined with other respiratory diseases increases the risk of death from 
respiratory failure. In addition, UDP occurred at a high rate, and reducing the occurrence of 
phrenic palsy may have reduced the risk of postoperative respiratory failure. The cause of 
UDP could not be established in this study. Future studies should be performed to clarify 
which surgical manipulations cause UDP. 
In addition, we searched for candidate genes for MR in Chihuahua. We examined 
polymorphisms in SERT, XPC, and DCHS1. However, we found no polymorphisms that may 
be involved in the development of MR. 
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The results of this study could contribute to improving the surgical outcome of MVD in dogs 
and reducing the incidence of complications. In the future, we will continue to search for 
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 UDP  
n = 86 
Non-UDP  
n = 198 
P  
 125.5 (58–168) 122.0 (59–176) p = 0.250 
kg  3.3 (1.6–10.2) 3.8 (1.7–13.5) p = 0.223 
VHS 11.9 (9.6–15.2) 12.0(8.8–15.6) p = 0.532 
LA/Ao 2.14 (1.37–3.26) 2.27 (1.20–4.44) p = 0.146 
LVIDDN 2.10 (1.13–3.14) 2.20 (1.07–3.22) p = 0.010 
 55 (32–118) 56 (34–148) p = 0.785 
 345 (238–1197) 331 (164–1036) p = 0.405 
 
 





6   
 
  95%  P  
 2.2 0.9 – 5.5 p = 0.08 
 10.5 1.4 – 81.0 p = 0.024 
 1.07 0.88 – 1.23 p = 0.500 
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I 8 &+$JM!-0B"; 
Gene Exon 5’ - primer 3’ - primer 	() 
() 
SERT 1 TGCGTAACTCTGTTCTCC AGACATGATCACTGCTCTGG 60 30 
SERT 2 GTGAGGTCATTCAACACAGG CTGATTCCAGAAGAAGGTCC 60 30 
SERT 3 TTACCACATTGCCACCTGCC AGAGTGGGGTCCAGGAAGAA 62 45 
SERT 4 AAGGAGATGCCTGAAAGTCCG 
GGGCCATGATCAGTGCGTTA 
TCACACAATGGTTCTTGGGATTG 62 30 
SERT 5-6 CAAATGGAATTGGCCTGGGG 62 60 
SERT 7 CCAACCAGTCTGAGAGGCAG 
TCATTGTTGGTGTGGCTGAG 
GGACTCATTGCCAGACCCAA 62 30 
SERT 8  TCAAGAGCACCACAGTGAGG 60 30 
SERT 9 CTACTCATGACCAGCAAC CCAGATACTCTGTCAAGC 55 30 
SERT 10 AGTGCTCCATAGGACAGG TTGTGGTAGAGCGTGAAG 60 30 
SERT 11 CGTCTCAACTTCAGAGCAG GATGTGACACATGCAGCAG 60 30 
SERT 12 GCCCTGAAGGGGTTGCTTTA TGCCACTGCATCTAAGGCTC 62 45 
SERT 13 AATTGGGAATTCCTTTCATGAGG AGGCCATATTTGCCTGTGGA 62 60 
XPC 16 ATAAACATCTTTGCATTTGGCAGC CTTCTGTGCTTTCTTAGAGGAGAT 60 30 
DCHS1 19 TGATAATCGTCCCACCATCC AGGTGGTAGGAAATGTGACC 60 60 
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